Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
Sponsor: Vanda Pharmaceuticals
Summary
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
Official title: Open-label Safety Study of a 1-year 8 to 24 mg/Day Dose Regimen of Iloperidone (FANAPT®) in Adolescent Patients With Schizophrenia or Bipolar I Disorder
Key Details
Gender
All
Age Range
12 Years - 17 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2023-05-24
Completion Date
2026-11-30
Last Updated
2025-03-04
Healthy Volunteers
No
Conditions
Interventions
Iloperidone
oral tablet
Locations (9)
Vanda Investigational Site
Little Rock, Arkansas, United States
Vanda Investigational Site
Denver, Colorado, United States
Vanda Investigational Site
Atlanta, Georgia, United States
Vanda Investigational Site
Atlanta, Georgia, United States
Vanda Investigational Site
Decatur, Georgia, United States
Vanda Investigational Site
Cincinnati, Ohio, United States
Vanda Investigational Site
Garfield Heights, Ohio, United States
Vanda Investigational Site
Westlake, Ohio, United States
Vanda Investigational Site
Everett, Washington, United States